Ashina, M., Goadsby, P. J., Reuter, U., Silberstein, S., Dodick, D., Rippon, G. A., . . . Mikol, D. D. (2019). Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia.
Παραπομπή Chicago StyleAshina, Messoud, et al. "Long-term Safety and Tolerability of Erenumab: Three-plus Year Results From a Five-year Open-label Extension Study in Episodic Migraine." Cephalalgia 2019.
Παραπομπή MLAAshina, Messoud, et al. "Long-term Safety and Tolerability of Erenumab: Three-plus Year Results From a Five-year Open-label Extension Study in Episodic Migraine." Cephalalgia 2019.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.